We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
Read MoreHide Full Article
Axsome Therapeutics, Inc. (AXSM - Free Report) announced that it has initiated enrollment in the phase III study — SYMPHONY — which will evaluate its pipeline candidate, AXS-12, in patients with narcolepsy, a sleep disorder. Top-line data from the study is expected in 2023.
The company has successfully completed a phase II study evaluating the candidate in narcolepsy patients. Data from the mid-stage study demonstrated that treatment with AXS-12 resulted in a highly statistically significant reduction in the mean weekly number of cataplexy attacks from baseline compared to placebo, following a treatment period of two weeks. The treatment with AXS-12 also improved excessive daytime sleepiness by reducing the frequency of inadvertent naps in patients.
The candidate enjoys Orphan Drug Designation for the treatment of narcolepsy in the United States. However, the candidate lost its Breakthrough Therapy designation in July this year. The company stated that the FDA repealed the Breakthrough Therapy designation, following its approval to another drug, most likely Harmony Biosciences’ (HRMY - Free Report) Wakix, as the first and only non-scheduled treatment for narcolepsy patients. We note that apart from Harmony Biosciences, Axsome will also face stiff competition from Jazz Pharmaceuticals (JAZZ - Free Report) that has a strong sleep disorder portfolio with a couple of drugs approved to treat narcolepsy.
We also note that Axsome has an exclusive license agreement with Pfizer (PFE - Free Report) for the non-clinical and clinical data on the latter’s reboxetine, the active pharmaceutical ingredient in AXS-12 that will support the potential new drug application (NDA) for the candidate.
Shares of Axsome have plunged 65% so far this year compared with the industry’s decrease of 0.1%.
Image Source: Zacks Investment Research
The company’s leading pipeline candidates are AXS-05 and AXS-07 for which NDAs have been filed with the FDA seeking their approval. While the company is seeking approval for AXS-05 as a treatment of major depression disorder, AXS-07’s NDA is for acute treatment of migraine. A decision from the FDA related to the approval of AXS-07 is expected by April-end in 2022. In July, the FDA notified the company that it has identified deficiencies within the NDA that preclude labeling discussions at the time and has extended the review period of the NDA for AXS-05. The new PDUFA target action date is yet to be informed by the FDA.
Axsome is also developing AXS-05 as a potential remedy for treatment-resistant depression, smoking cessation, and agitation associated with Alzheimer's disease. The company has another candidate, AXS-14, in its pipeline that is in late-stage development as a potential treatment for the management of fibromyalgia, a debilitating central nervous system disorder with limited treatment options.
Image: Bigstock
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
Axsome Therapeutics, Inc. (AXSM - Free Report) announced that it has initiated enrollment in the phase III study — SYMPHONY — which will evaluate its pipeline candidate, AXS-12, in patients with narcolepsy, a sleep disorder. Top-line data from the study is expected in 2023.
The company has successfully completed a phase II study evaluating the candidate in narcolepsy patients. Data from the mid-stage study demonstrated that treatment with AXS-12 resulted in a highly statistically significant reduction in the mean weekly number of cataplexy attacks from baseline compared to placebo, following a treatment period of two weeks. The treatment with AXS-12 also improved excessive daytime sleepiness by reducing the frequency of inadvertent naps in patients.
The candidate enjoys Orphan Drug Designation for the treatment of narcolepsy in the United States. However, the candidate lost its Breakthrough Therapy designation in July this year. The company stated that the FDA repealed the Breakthrough Therapy designation, following its approval to another drug, most likely Harmony Biosciences’ (HRMY - Free Report) Wakix, as the first and only non-scheduled treatment for narcolepsy patients. We note that apart from Harmony Biosciences, Axsome will also face stiff competition from Jazz Pharmaceuticals (JAZZ - Free Report) that has a strong sleep disorder portfolio with a couple of drugs approved to treat narcolepsy.
We also note that Axsome has an exclusive license agreement with Pfizer (PFE - Free Report) for the non-clinical and clinical data on the latter’s reboxetine, the active pharmaceutical ingredient in AXS-12 that will support the potential new drug application (NDA) for the candidate.
Shares of Axsome have plunged 65% so far this year compared with the industry’s decrease of 0.1%.
Image Source: Zacks Investment Research
The company’s leading pipeline candidates are AXS-05 and AXS-07 for which NDAs have been filed with the FDA seeking their approval. While the company is seeking approval for AXS-05 as a treatment of major depression disorder, AXS-07’s NDA is for acute treatment of migraine. A decision from the FDA related to the approval of AXS-07 is expected by April-end in 2022. In July, the FDA notified the company that it has identified deficiencies within the NDA that preclude labeling discussions at the time and has extended the review period of the NDA for AXS-05. The new PDUFA target action date is yet to be informed by the FDA.
Axsome is also developing AXS-05 as a potential remedy for treatment-resistant depression, smoking cessation, and agitation associated with Alzheimer's disease. The company has another candidate, AXS-14, in its pipeline that is in late-stage development as a potential treatment for the management of fibromyalgia, a debilitating central nervous system disorder with limited treatment options.
Axsome Therapeutics, Inc. Price
Axsome Therapeutics, Inc. price | Axsome Therapeutics, Inc. Quote
Zacks Rank
Axsome currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.